Login to Your Account



Two pipeline additions as Sciclone aims for green channel speed to approval in China

By Shannon Ellis
Staff Writer

Friday, May 13, 2016

SHANGHAI – In China's evolving regulatory and pricing environment, Sciclone Pharmaceuticals Inc., has managed to keep growing its bottom line with lead drug Zadaxin (thymalfasin), an imported drug manufactured in Italy for the treatment of hepatitis B, hepatitis C, certain cancers and as a vaccine adjuvant.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription